Study findings suggested that high expression of DNMT3A was significantly related to worse OS and progression-free survival (PFS) in patients with PGI-DLBCL patients treated with R-CHOP regimen.54DNMT3A mutation was found to be correlated with shorter PFS in AITL patients.133 Since DNMT3A mutations were significantly decreased after therapy,139 they could serve as sensitive indicators in circulating tumor DNA (ctDNA) and provide a noninvasive method of monitoring minimal residual disease in AITL.140. The gene discussed is DNMT3A; the disease is angioimmunoblastic T-cell lymphoma.